Name:
Institution:
Type:
PI
Grant Award Details
Chimeric Antigen Receptor Targeting Spike Glycoprotein of SARS-cov2
Grant Type:
Grant Number:
DISC2COVID19-12016
Project Objective:
- To develop an allogeneic, iPSC-derived CAR NK cell therapy targeting SARS-CoV-2
Investigator:
Disease Focus:
COVID-19
Infectious Disease
Respiratory Disorders
Human Stem Cell Use:
iPS Cell
Award Value:
$249,996
Status:
Active
Grant Application Details
Application Title:
- Chimeric Antigen Receptor Targeting Spike Glycoprotein of SARS-cov2
Public Abstract:
Research Objective
We expect to generate iPSC derived NK cells expressing a CAR against SARS-cov2 that could be used as an off-the-shelf therapy for COVID-19
Impact
The proposed studies will provide a novel therapeutic approach to boost the cellular immunity against SARS-cov2, especially for high risk populations.
Major Proposed Activities
- Construction of SARS-cov2 CAR constructs
- Generation of iPSC-derived NK cells expressing CARs
- Differentiation of iPSC-CAR cells into hematopoietic progenitors
- Derivation of human NK-CAR cells
- In vitro studies of iPSC derived NK-CAR cells
- In vivo studies of iPSC-derived NK CAR cells
Statement of Benefit to California:
The SARS-cov2 is the etiological agent of COVID-19, a global pandemic that has caused more than 4200 deaths in California. The proposed studies will provide a novel therapeutics to improve the immune response to COVID-19.
